Video

Vibegron shows efficacy among patients with OAB

Author(s):

Urology Times staff

“This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well,” says Cornelia Haag-Molkenteller, MD. PhD.

In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the background and findings of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.

Related Videos
Ravi Munver, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Benjamin Pockros, MD, MBA, answers a question during a Zoom video interview
Related Content
Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence
August 28th 2024

Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence

Hannah Clarke
Over 12 weeks, the average reduction in total UI frequency was 2.3 episodes per day among those in the pelvic yoga program compared with 1.9 episodes per day among those in the general physical conditioning program.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Trial progresses of SNM device for urge urinary incontinence
July 23rd 2024

Trial progresses of SNM device for urge urinary incontinence

Hannah Clarke
Data from phase 2 of the SANS-UUI trial are expected to support an application to the FDA for approval of the device in patients with urge urinary incontinence.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Digital health treatment program found safe, effective for urinary incontinence
July 10th 2024

Digital health treatment program found safe, effective for urinary incontinence

Hannah Clarke
"We believe the collective findings are unique in urogynecology and offer strong evidence that first-line incontinence treatment is effective, and women can access it using the Leva System,” says Evelyn Hall, MD.
Study progresses of oral compound for overactive bladder
July 9th 2024

Study progresses of oral compound for overactive bladder

Hannah Clarke
The phase 1b trial enrolled 51 female patients with OAB to assess the safety, tolerability, and preliminary efficacy of V117957.
© 2024 MJH Life Sciences

All rights reserved.